PATIENT PROFILES

Wendy Dakota Jordan Morgan Erin

Take a closer look at the types of patients who may benefit from NEMLUVIO

WENDY

Severe Itch/Lower
Skin Involvement

Dakota

Moderate or Severe 
Itch/Moderate 
Skin Involvement

Jordan

Sensitive Areas

Morgan

Frequent Flares

Erin

Moderate Itch/
Severe Skin 
Involvement

Actual patient image. 
Story based on real patients who suffer from atopic dermatitis.

Wendy and her spouse can't sleep well due to her continuous itching

Age: 32 years

Signs and Symptoms:

  • Itch score of 7+
  • BSA ~15%
  • Uncontrolled scratching and waking at night
  • Superficial skin infections
Itch scale from 0 to 10, with a score of 7-10 showing on the scale.Itch scale from 0 to 10, with a score of 7-10 showing on the scale.

Actual patient image. 
Story based on real patients who suffer from atopic dermatitis.

Actual patient image. 
Story based on real patients who suffer from atopic dermatitis.

Dakota wishes the itch would stop interfering with their sleep and daily life

Age: 35 years

Signs and Symptoms:

  • QoL impact or Itch score of 4+
  • BSA 20%
  • Vocal about the itch
  • Adjunct therapy for sleep or itch (antihistamines or prednisone)
Itch scale from 0 to 10, with a score of 4-10 showing on the scale.Itch scale from 0 to 10, with a score of 4-10 showing on the scale.

Actual patient image. 
Story based on real patients who suffer from atopic dermatitis.

Actual patient image. 
Story based on real patients who suffer from atopic dermatitis.

Jordan's itchy areas are very sensitive and feels awkward scratching these areas in public

Age: 38 years

Signs and Symptoms:

  • Itch score of 4+
  • BSA ~15%
  • Face, scalp, hands, or genital involvement
  • Itch can be very embarrassing
Itch scale from 0 to 10, with a score of 4-10 showing on the scale.Itch scale from 0 to 10, with a score of 4-10 showing on the scale.

Actual patient image. 
Story based on real patients who suffer from atopic dermatitis.

Actual patient image. 
Story based on real patients who suffer from atopic dermatitis.

Morgan is unable to concentrate at school due to their constant itching

Age: 16 years

Signs and Symptoms:

  • Itch score of 6+
  • BSA 25%
  • Moderate itch that drives worsening
  • Highly variable skin
  • Impacting daily life
  • Frequent need for oral steroids
Itch scale from 0 to 10, with a score of 6-10 showing on the scale.Itch scale from 0 to 10, with a score of 6-10 showing on the scale.

Actual patient image. 
Story based on real patients who suffer from atopic dermatitis.

Actual patient image. 
Story based on real patients who suffer from atopic dermatitis.

Erin worries their scratching and flaking makes family time awkward

Age: 41 years

Signs and Symptoms:

  • Itch score of 4+
  • BSA ~50%
  • Thickened lesions/lichenification
  • Wearing clothes to cover up scabs and scratches
Itch scale from 0 to 10, with a score of 4-10 showing on the scale.Itch scale from 0 to 10, with a score of 4-10 showing on the scale.

Actual patient image. 
Story based on real patients who suffer from atopic dermatitis.

Lasting Skin Healing1

Discover how NEMLUVIO helped most patients with AD achieve lasting skin clearance1

SEE THE DIFFERENCE 

Frequently Asked Questions

Questions about NEMLUVIO? 
We have the answers

LEARN MORE 

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

  • the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
  • the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

  • Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia. 
  • Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular. 

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.